Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 1/20 | 0.33 |
| ▸ | BTK | Q06187 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 3/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.30 |
| ▸ | ATM | Q13315 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23411138 | 0.94 | JAK2 (0.33) | JAK2BTKMEN1KMT2APKM | |
| SCHEMBL29891802 | 0.94 | JAK2 (0.33) | JAK2BTKMEN1KMT2APKM | |
| SCHEMBL23411629 | 0.82 | ESR2 (0.41) | JAK2BTKMEN1KMT2APKM | |
| SCHEMBL782441 | 0.80 | MEN1 (0.41) | MEN1KMT2APKMTSHRPSMD14 | |
| SCHEMBL31180321 | 0.80 | MEN1 (0.41) | MEN1KMT2APKMTSHRPSMD14 | |
| SCHEMBL17419138 | 0.77 | MEN1 (0.41) | MEN1KMT2APKMTSHRPSMD14 | |
| SCHEMBL4822294 | 0.73 | ATM (0.45) | MEN1KMT2APKMATMALDH1A1 | |
| SCHEMBL9372564 | 0.73 | ATM (0.53) | MEN1KMT2APKMATMALDH1A1 | |
| SCHEMBL2384145 | 0.73 | ESR2 (0.41) | JAK2BTKMEN1KMT2ATSHR | |
| SCHEMBL29811309 | 0.73 | ESR2 (0.41) | JAK2BTKMEN1KMT2ATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3190104-B1 | QUINOLINONE COMPOUND AND USE THEREOF | SUNSHINE LAKE PHARMA CO LTD (CN) | 2021-10-27 | — | — | EP | disclosed |
| US-10065928-B2 | Quinolinone compound and use thereof | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2018-09-04 | — | — | US | disclosed |
| US-20170247332-A1 | QUINOLINONE COMPOUND AND USE THEREOF | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2017-08-31 | — | — | US | disclosed |
| EP-3190104-A1 | QUINOLINONE COMPOUND AND USE THEREOF | Sunshine Lake Pharma Co., Ltd. (CN) | 2017-07-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170247332-A1 | QUINOLINONE COMPOUND AND USE THEREOF | HIF1AN, HIF1A, EGLN2 | JAK2 27/4885BTK 4093/4885MEN1 3273/4885 |
| US-10065928-B2 | Quinolinone compound and use thereof | HIF1AN, HIF1A, EGLN2 | JAK2 27/4885BTK 4093/4885MEN1 3273/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.